We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A coalition of muscular dystrophy advocates, researchers, clinicians and drug manufacturers has submitted the first-ever patient-initiated draft guidance on drug development to the FDA, a move prompted by the agency’s efforts to get more patient perspectives into the drug approval process. Read More
International authorities recently seized more than $31 million in potentially counterfeit and dangerous drugs and shuttered over 10,600 websites for peddling unapproved and substandard pharmaceuticals, in the third annual international sweep of its kind. Read More
Sponsors of biosimilars need to demonstrate how their products compare with reference drugs, including pharmacokinetic and pharmacodynamic data to show compatibility in clinical trials, according to U.S. Food and Drug Administration draft guidance on non-brand versions of the complex therapies. Read More
The U.S. Food and Drug Administration has been quicker to approve new active substances over the last decade than both its European and Japanese counterparts, a recent study finds. Read More
British drugmaker GlaxoSmithKline is facing another bribery probe, this time from a UK watchdog that plans to investigate the company’s global business practices. Read More
U.S. and European regulators have made strides toward mutual recognition of quality inspections, so that companies inspected by one regulator won’t face a second inspection by the other, but setbacks remain, a top EU regulatory official told IPRM. Read More
The U.S. Food and Drug Administration is trying to encourage mobile app and web developers to give wide distribution to drug adverse event information by providing the data in an easy-to-use electronic format. Read More
Europe’s major pharma association is criticizing a decision by Italian regulators that would allow the government to pay for an off-label eye treatment, saying the move is motivated by cost savings and could undermine the EU’s regulatory authority. Read More
Manufacturers looking to speed up drug approvals in the EU and ensure that their products are covered by payers should initiate parallel conversations with the European Medicines Agency and health technology assessment bodies early in the development process, the EMA says. Read More